Disparate Eosinophilic Phenotypes with Age: Impact on Eligibility for Anti-IL-5 Therapies in Severe Asthma
- PMID: 31706492
- DOI: 10.1016/j.jaip.2019.07.010
Disparate Eosinophilic Phenotypes with Age: Impact on Eligibility for Anti-IL-5 Therapies in Severe Asthma
Comment on
-
Proportion of Severe Asthma Patients Eligible for Mepolizumab Therapy by Age and Age of Onset of Asthma.J Allergy Clin Immunol Pract. 2019 Nov-Dec;7(8):2689-2696.e2. doi: 10.1016/j.jaip.2019.05.053. Epub 2019 Jun 13. J Allergy Clin Immunol Pract. 2019. PMID: 31201938
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
